Clinical
Time to flourish
Failure is going to be part of the process with biosimilars, but for companies with an entrepreneurial spirit and a clear mindset, the rewards are also there...
More Clinical Articles
Clinical
GSK Clinical Trial Questionnaire: Most Valuable Patient Initiative
A move towards greater patient centricity was behind GSK's desire to get systematic feedback from participants in clinical trials – and the company hopes its blueprint can be taken up by rivals.
Clinical
Engineering a Culture of Innovation Part 2: Social Contracts
Continuing the recent interview with Henry Doss, ecosystem architect and co-author of ‘The Rainforest Scorecard: A Practical Framework for Growing Innovation Potential', we now look more closely at the elements of engineering a culture of innovation.
Clinical
Size Matters
Dr Robert Langer was the recent recipient of the Queen Elizabeth Prize in Engineering, for his groundbreaking research into controlled, targeted drug delivery. eyeforpharma unravels his past achievements, discusses his present research and offers his future vision of medicine.
Clinical
Right on target
US President Barack Obama recently pledged $215m for his precision medicine initiative. Danielle Barron discusses the future of precision medicine with InnVentis founder and CEO Thomas Wilckens, and examines the impact this will have on the current R&D environment.
Clinical
A Good Story Can Keep an Organization Afloat
Everyone likes a good story, but do they really have a place within pharma? We spoke to Ian Sanders, Creative Consultant and Business Storyteller, to find out.
Clinical
The Site Experience: Using Technology to Advance Clinical Research
Dr Vivienne van de Walle offers 9 steps pharma companies can take to improve clinical trials based on her own insights and conversations with other investigators, who agree that using eClinical technologies to collect patient data can improve compliance and data quality, and reduce monitoring time.
Clinical
Ensuring Safer Drugs to Market
We report on some of the key debates taking centre stage at the 8th Pharmacovigilance Conference, held recently, including the implications of emerging markets, utilizing new and emerging technologies, risk management strategies, and shifting towards patient-centricity.
Clinical
The Innovation Blind Spot
Danielle Barron talks to author Ron Adner whose book “The Wide Lens” explains why the failure to focus on the entire ecosystem rather than the immediate environment of a new product is the downfall of pharmaceutical companies attempting to successfully commercialize innovation.
Access and Evidence
Real World Evidence: Maximize Benefits To Healthcare
With a staggering cost of drug development estimated at US$2.6 billion and a high failure rate of new compounds, pharma is under pressure to develop solutions that improve the R&D hit rate. Real World Evidence combined with digital healthcare might be what the industry is looking for.